| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/17/2005 | DE10332854A1 Verwendung des neu-identifizierten humanen Gens 7a5/Prognostin für Tumordiagnostik und Tumortherapie Using the newly-identified human gene 7a5 / Prognostin for tumor diagnosis and tumor therapy |
| 02/17/2005 | CA2678736A1 Novel multifunctional il-2 - il-18 fusion proteins |
| 02/17/2005 | CA2575591A1 A pharmaceutical composition for treatment of cancers |
| 02/17/2005 | CA2555323A1 Polypeptide specific to liver cancer, polynucleotide coding for the polypeptide, and rna molecule suppressing expression of the polypeptide |
| 02/17/2005 | CA2537555A1 Compositions and methods for the therapy and diagnosis of lung cancer |
| 02/17/2005 | CA2535506A1 Pharmaceutical compositions for preventing breast and ovarian cancer |
| 02/17/2005 | CA2535260A1 Method for treating cachexia with retinoid ligands |
| 02/17/2005 | CA2535125A1 Pyridylpyrrole derivatives active as kinase inhibitors |
| 02/17/2005 | CA2535066A1 Macrophage activation inhibitor |
| 02/17/2005 | CA2534898A1 Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| 02/17/2005 | CA2534658A1 Trefoil factor 3 (tff3) as a target for anti-cancer therapy |
| 02/17/2005 | CA2534528A1 3-(indol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones,3-(benzimidazol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones, and 3-(indolin-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones; their preparationand use as modulators of apoptosis |
| 02/17/2005 | CA2534496A1 Pyrimidylpyrrole derivatives active as kinase inhibitors |
| 02/17/2005 | CA2534471A1 Method and apparatus for producing ultrafine drug particles |
| 02/17/2005 | CA2534415A1 Therapeutic delivery of carbon monoxide |
| 02/17/2005 | CA2534292A1 Substituted imidazopyrimidines for the prevention and treatment of cancer |
| 02/17/2005 | CA2533990A1 Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
| 02/17/2005 | CA2533861A1 Combinations comprising staurosporines |
| 02/17/2005 | CA2533540A1 Targeted therapeutic vaccine against p-glycoprotein 170 for inhibiting multi-drug resistance in the treatment of cancers |
| 02/17/2005 | CA2533335A1 Substituted lactams and their use as anti-cancer agents |
| 02/17/2005 | CA2532948A1 Combinations of a cathepsin k inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss |
| 02/17/2005 | CA2528606A1 Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium |
| 02/17/2005 | CA2526274A1 Prostate stem cell antigen (psca) variants and subsequences thereof |
| 02/17/2005 | CA2521481A1 Catheter balloon systems and methods |
| 02/17/2005 | CA2502148A1 Methods and compositions for increasing the efficacy of biologically-active ingredients |
| 02/16/2005 | EP1507007A1 Cell cycle related proteins |
| 02/16/2005 | EP1507005A2 Antisense modulation of BCL-X expression |
| 02/16/2005 | EP1506967A1 Dipeptidyl peptidase inhibitors |
| 02/16/2005 | EP1506962A2 Nitrogen-containing aromatic heterocycles |
| 02/16/2005 | EP1506960A1 Indole compounds as inhibitors of tubulin polymerisation for the treatment of angiogenesis-related disorders |
| 02/16/2005 | EP1506784A1 Identification of novel factors that block programmed cell death or apoptosis by targeting JNK |
| 02/16/2005 | EP1506779A1 (3-(4-(Pyridin-2-ylamino)-butyryl)-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-9-yl)-acetic acid derivatives and related tricyclic indanyls as alphaVbeta3 and alphaVbeta5 integrin inhibitors for the treatment of cancer and unstable angina |
| 02/16/2005 | EP1506778A1 TGF-a EXPRESSION INHIBITORS |
| 02/16/2005 | EP1506409A1 Assays for modulators of asparaginyl hydroxylase |
| 02/16/2005 | EP1506317A2 Marker molecules associated with lung tumors |
| 02/16/2005 | EP1506315A2 Method of identifying pancreatic ductal carcinoma (pdc) specific genes using pancreatic ductal cells, method of testing for pdc using said genes, and method of screening pharmaceutical candidate compounds for treating or preventing pdc |
| 02/16/2005 | EP1506301A1 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |
| 02/16/2005 | EP1506286A2 Neutralizing human anti-igfr antibody |
| 02/16/2005 | EP1506285A2 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| 02/16/2005 | EP1506218A2 Reversible modification of membrane interaction |
| 02/16/2005 | EP1506204A2 1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof |
| 02/16/2005 | EP1506200A2 Novel diazabicyclic biaryl derivatives |
| 02/16/2005 | EP1506192A1 Substituted pyrroline kinase inhibitors |
| 02/16/2005 | EP1506189A1 Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| 02/16/2005 | EP1506188A1 Process for the preparation of a hydrate of an anthranilic acid derivative |
| 02/16/2005 | EP1506187A1 2-thio-substituted imidazole derivatives and their use in pharmaceutics |
| 02/16/2005 | EP1506186A1 Substituted heterocyclic compounds and methods of use |
| 02/16/2005 | EP1506181A1 Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
| 02/16/2005 | EP1506180A1 Thiazolidine-4-one derivative, method for preparing the same, and pharmaceutical composition containing the same |
| 02/16/2005 | EP1506178A2 Bicyclic modulators of androgen receptor function |
| 02/16/2005 | EP1506176A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/16/2005 | EP1506175A1 N-substituted tricyclic 3-aminopyrazoles as pdgf receptor inhibitors |
| 02/16/2005 | EP1506174A2 Opioid and opioid-like compounds and uses thereof |
| 02/16/2005 | EP1506166A1 Aminotetralin-derived urea modulators of vanilloid vr1 receptor |
| 02/16/2005 | EP1506021A2 Novel use of adenoviruses and nucleic acids coding therefor |
| 02/16/2005 | EP1506019A1 Complexes for the delivery of biologically-active material to cells |
| 02/16/2005 | EP1506018A1 Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s) |
| 02/16/2005 | EP1506011A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 02/16/2005 | EP1506010A2 Methylated immunostimulatory oligonucleotides and methods of using the same |
| 02/16/2005 | EP1506004A2 Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated pp2ac |
| 02/16/2005 | EP1505993A1 Sensitization of neoplastic cells to radiation therapy with oncolytic viruses |
| 02/16/2005 | EP1505992A1 Method for reducing pain using oncolytic viruses |
| 02/16/2005 | EP1505974A2 Use of compounds that are effective as selective opiate receptor modulators |
| 02/16/2005 | EP1505973A2 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
| 02/16/2005 | EP1505970A1 Methods of using thiazolidine derivatives to treat cancer or inflammation |
| 02/16/2005 | EP1505959A1 Use of edg receptor binding agents in cancer |
| 02/16/2005 | EP1505942A2 Pathogen vaccines and methods for using the same |
| 02/16/2005 | EP1505930A2 Drug-delivery endovascular stent and method for treating restenosis |
| 02/16/2005 | EP1421099B1 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
| 02/16/2005 | EP1397365B1 Heteroaryl-diazabicyclo-alkanes as cns-modulators |
| 02/16/2005 | EP1395553B1 Pyrrolidine derivatives as factor xa inhibitors |
| 02/16/2005 | EP1311519A4 Thermosensitive cyclotriphosphazene-platinum complex conjugate, its preparation method and anticancer agent containing the same |
| 02/16/2005 | EP1296698A4 Therapeutic agents - ii |
| 02/16/2005 | EP1296697A4 Therapeutic agents - i |
| 02/16/2005 | EP1281709B1 Novel heterocyclic compounds with anti-inflammatory activity |
| 02/16/2005 | EP1246814B1 Compounds and methods for modulation of estrogen receptors |
| 02/16/2005 | EP1244617B1 Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone |
| 02/16/2005 | EP1240166B1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl carboxamide inhibitors of cyclin dependent kinases |
| 02/16/2005 | EP1215203B1 Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient |
| 02/16/2005 | EP1064285B1 Novel cephalotaxane derivatives and process for their preparation |
| 02/16/2005 | EP0634896B1 Evaluation of patients with progressive immunosuppression |
| 02/16/2005 | CN1582301A Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 02/16/2005 | CN1582287A Thiophenylthiopyrane dioxides as MMP or TNF-alpha inhibitors |
| 02/16/2005 | CN1582285A Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (GSK3 inhibitors) |
| 02/16/2005 | CN1582284A Aminopyrimidines and pyridines |
| 02/16/2005 | CN1582280A 3, 4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| 02/16/2005 | CN1582278A Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same |
| 02/16/2005 | CN1582277A Amide derivatives as glycogen synthase kinase 3-beta inhibitors |
| 02/16/2005 | CN1582275A Calcium antagonistic compound |
| 02/16/2005 | CN1582274A Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| 02/16/2005 | CN1582271A Inhibitors of integrin alpha v beta 6 |
| 02/16/2005 | CN1582166A Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| 02/16/2005 | CN1582165A Antibodies to CD40 |
| 02/16/2005 | CN1582164A Antigen arrays for treatment of bone disease |
| 02/16/2005 | CN1582160A Novel herbal chemical composition for treatment of cancer |
| 02/16/2005 | CN1582159A Preparing material of flavanol wood lipid with increased solubility |
| 02/16/2005 | CN1582150A Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
| 02/16/2005 | CN1582148A Derivatives of phenoxy-n-'4-(isothiazolidin-1, 1-dioxid-2yl)pheny!-valerian- acid amide and other compounds as inhibitors of the coagulation factor Xa in the treatment of thromboembolic diseases and tu |
| 02/16/2005 | CN1582147A Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them |
| 02/16/2005 | CN1580264A High soluble expressed tricholsanthin mutant and its preparing method |